Association of transforming growth factor-β1 with prostate cancer: An immunohistochemical study

doi:10.1016/0046-8177(93)90055-L

Human Pathology

Volume 24, Issue 1, January 1993, Pages 4-9

https://doi.org/10.1016/0046-8177(93)90055-L Get rights and content

Abstract

Prostate tissue samples from patients with prostatic carcinoma (PC) and/or benign prostatic hyperplasia (BPH) were examined for expression of transforming growth factor-β₁ (TGF-β₁) using an immunohistochemical technique. Tissues were stained with CC and LC antisera, which react with extracellular and intracellular TGF-β₁, respectively. All PC and BPH tissues showed positive extracellular staining; however, CC-immunoreactive material was significantly more extensive in PC compared with BPH, the average positively staining areas being 59% and 26%, respectively. This differential staining pattern was evident in cases in which areas of PC were located adjacent to areas of BPH. LC staining was identified exclusively intracellularly involving both stromal and epithelial cells in cases of PC as well as BPH. However, while stromal cell staining was more pronounced in BPH, epithelial cell staining tended to be more extensive and more intense in PC. The findings suggest that TGF-β₁ may be biologically important in the development of PC and BPH.

References (31)

H Armenian et al.
Relation between benign prostatic hyperplasia and cancer of the prostate
Lancet
(1974)
TC Thompson et al.
Multistage carcinogenesis induced in ras and myc oncogenes in a reconstituted organ
Cell
(1989)
EP Sandgren et al.
Overexpression of TGF-α in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia and carcinoma of the breast
Cell
(1990)
EJ Battegay et al.
TGF-β induces biomodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop
Cell
(1990)
RA Ignotz et al.
Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix
J Biol Chem
(1986)
E Silverberg et al.
Cancer statistics, 1990
CA Cancer J Clin
(1990)
HB Carter et al.
The prostate—An increasing medical problem
Prostate
(1990)
JE McNeal
Origin and evolution of benign prostatic enlargement
Invest Urol
(1978)
JE McNeal et al.
Zonal distribution of prostate adenocarcinoma: Correlation with histological pattern and direction of spread
Am J Surg Pathol
(1988)
P Greenwald et al.
Cancer of the prostate among men with benign prostatic hyperplasia
J Natl Cancer Inst
(1974)

TC Thompson

Oncogenes and growth factors in prostate cancer

Cancer Cells

(1990)

H Mori et al.

Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia

Prostate

(1990)

DM Peehl et al.

Activated Ki-ras oncogene in human prostate adenocarcinoma

Prostate

(1987)

BS Carter et al.

ras Gene mutations in human prostate cancer

Cancer Res

(1990)

PH Gumerlock et al.

Activated ras alleles in human carcinoma of the prostate are rare

Cancer Res

(1991)

Cited by (176)

Regulation of immunophenotype modulation of monocytes-macrophages from M1 into M2 by prostate cancer cell-culture supernatant via transcription factor STAT3
2018, Immunology Letters
Citation Excerpt :
Regulation of inducible Nitric Oxide Synthase (iNOS) at the transcriptional level and of TNF-α at the post-transcriptional level [44] explains why nitric oxide and TNF-α were nearly undetectable in the PC3 incubation group. An elevated concentration of TGF-β has also been demonstrated in a prostate cancer-cell line and is associated with tumor progression and metastasis [47–49]. The M2-like phenotype is an important immunological cell that produces and secretes this growth factor.
Transcription factor STAT3 has a prominent innate immunity effect on cancer progression. We determined the regulation of STAT3 in the immunophenotype modulation of macrophages from M1 into M2 induced by the cell-culture supernatant of the Prostate-Cancer line PC3.
Monocytes-macrophages from healthy donors were cultured in the supernatant of PC3 cells, membrane proteins, and intracytoplasmic and phosphorylated STAT3 were measured using flow cytometry, while cytokines and growth factors were studied using luminescence. Cytotoxicity and nitric oxide were evaluated via colorimetric assays.
The supernatant of PC3 prostate-tumor cells effectively induced macrophages toward an M2 profile, and the expression of phosphorylated STAT3 in the monocytes-macrophages notably increased, and mainly related to IL-10. In the group of monocytes-macrophages treated with a STAT3 inhibitor, the macrophages were induced toward an M1 phenotype.
In this study, we showed that the secretion profile of PC3 prostate-cancer cells induces a change in macrophage phenotype from M1 into M2, and that the phenomenon is related to phosphorylation of transcription factor STAT3 and IL-10.
Id-1 promotes TGF-β1-induced cell motility through HSP27 activation and disassembly of adherens junction in prostate epithelial cells
2007, Experimental Cell Research
Id-1 (inhibitor of differentiation or DNA binding-1) has been positively associated with cell proliferation, cell cycle progression, and invasiveness during tumorigenesis. In addition, Id-1 has been shown to modulate cellular sensitivity to TGF-β1 (transforming growth factor β1). Here we demonstrate a novel role of Id-1 in promoting TGF-β1-induced cell motility in a non-malignant prostate epithelial cell line, NPTX. We found that Id-1 promoted F-actin stress fiber formation in response to TGF-β1, which was associated with increased cell–substrate adhesion and cell migration in NPTX cells. In addition, this positive effect of Id-1 on TGF-β1-induced cell motility was mediated through activation of MEK–ERK signaling pathway and subsequent phosphorylation of HSP27 (heat shock protein 27). Furthermore, Id-1 disrupted the adherens junction complex in TGF-β1-treated cells through down-regulation of E-cadherin, redistribution of β-catenin, along with up-regulation of N-cadherin. These lines of evidence reveal a novel tumorigenic role of Id-1 through reorganization of actin cytoskeleton and disassembly of cell–cell adhesion in response to TGF-β1 in human prostate epithelial cells, and suggest that intracellular Id-1 levels might be a determining factor for switching TGF-β1 from a growth inhibitor to a tumor promoter during prostate carcinogenesis.
Molecular markers of prostate cancer
2006, Urologic Oncology: Seminars and Original Investigations
Citation Excerpt :
Transforming growth factor (TGF)-β1 is involved in the regulation of cellular proliferation, chemotaxis, cellular differentiation, immune response, and angiogenesis [129]. TGF-β1 has promoted cell motility and metastasis in prostate cancer models [130,131], and increased expression of TGF-β1 has been associated with tumor grade, pathologic stage, and the presence of lymph node metastasis [132–137]. Several studies [129,138–140] have shown an association between increased serum levels of TGF-β1 and prostate cancer invasion, progression and metastasis, while others [141–143] have indicated no correlation.
Although prostate-specific antigen (PSA) has evolved as a very useful tool for detection of prostate cancer, there remains an urgent need for more accurate biomarkers to diagnose prostate cancer and predict cancer-related outcomes. Recent advances in the study of proteomics and high throughput techniques have led to the discovery of many potential biomarkers for prostate cancer. This article briefly reviews the current status of PSA testing and discusses several candidate protein biomarkers for prostate cancer, as well as highlighting some recent proteomic discoveries with the potential to supplement or even replace PSA for the diagnosis and prognosis of prostate cancer.
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
2006, Cytokine and Growth Factor Reviews
TGF-β overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-β as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. We have developed a new immunotherapeutic approach for the treatment of malignant tumors based on the specific inhibition of TGF-β2 by the antisense oligodeoxynucleotide AP 12009. After providing preclinical proof of concept, we assessed safety and efficacy of AP 12009 in clinical phase I/II open-label dose escalation studies in high-grade glioma patients. Median survival time after recurrence exceeded the up to date literature data for chemotherapy. A phase I/II study in pancreatic carcinoma and malignant melanoma is currently ongoing. Our results implicate targeted TGF-β2 suppression as a promising therapeutic approach for malignant tumor therapy.
Leptin induces cell migration and the expression of growth factors in human prostate cancer cells
2004, American Journal of Surgery
Citation Excerpt :
However, during late tumorigenesis, most cancer cells lose the wild-type function of TGF-β1 owing to mutations in the TGF-β1 signaling pathway, and TGF-β1 instead acts as a growth accelerator to promote metastasis and tumor cell invasion. TGF-β1 messenger RNA has been found to be present in both benign and malignant PCa [15], and malignant PCa cells stain more positively for TGF-β1 than benign samples [16]. Furthermore, TGF-β1 levels are increased with invasive PCa and this correlates directly with prostate-specific antigen levels [17,18].
The adipocyte hormone leptin has been shown to increase migration and angiogenesis in epithelial cells. Therefore, we hypothesized that leptin would induce prostate cancer cell migration and growth factor expression in vitro.
Prostate cancer cell lines DU145 and PC-3 (androgen-resistant) were treated with leptin over time. Supernatants were assayed for growth factor expression via enzyme-linked immunosorbent assay (ELISA). Becton Dickinson-Falcon Transwell systems were used to assay leptin-induced migration.
Leptin significantly induced expression of vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1), and basic fibroblast growth factor (bFGF) in DU145 and PC-3 cells. Prostate cancer cell migration was enhanced by leptin and inhibited 50% to 70% with the addition of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) inhibitors.
The mitogenic effects of leptin on cancer cells, in combination with the increased migration and expression of growth factors, overall likely contributes to the progression of prostate cancer. Therefore, obesity associated with high leptin levels should be considered a risk factor in prostate cancer patients.
A review of the pathophysiological mechanisms underlying castration-resistant prostate cancer
2021, Research and Reports in Urology

View all citing articles on Scopus

^☆: Supported in part by a grant (CA50588) from the National Institutes of Health and the Veterans Affairs Medical Center.

View full text

Original contributionAssociation of transforming growth factor-β1 with prostate cancer: An immunohistochemical study☆

Abstract

Lancet

Cell

Cell

Cell

J Biol Chem

Cancer statistics, 1990

CA Cancer J Clin

The prostate—An increasing medical problem

Prostate

Origin and evolution of benign prostatic enlargement

Invest Urol

Zonal distribution of prostate adenocarcinoma: Correlation with histological pattern and direction of spread

Am J Surg Pathol

Cancer of the prostate among men with benign prostatic hyperplasia

J Natl Cancer Inst

Oncogenes and growth factors in prostate cancer

Cancer Cells

Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia

Prostate

Activated Ki-ras oncogene in human prostate adenocarcinoma

Prostate

ras Gene mutations in human prostate cancer

Cancer Res

Activated ras alleles in human carcinoma of the prostate are rare

Cancer Res

Original contribution
Association of transforming growth factor-β₁ with prostate cancer: An immunohistochemical study☆